Insiders bought 142K on the open market and sold nothing.
Get an email when LITS's executives or directors buy, or make a large sale outside a plan.
Trades · last 2 years
| Date | Insider | Trade | Shares | Price | Value | Of their stake | Filing |
|---|---|---|---|---|---|---|---|
| Jun 24 | James P Flynn Director | Bought | 25,000 | $0.86 | 22K | 25% | Form 4 |
| Dec 19, 2025 | James P Flynn Director | Bought | 70,000 | $1.40 | 98K | 233% | Form 4 |
| Dec 18, 2025 | Alexander Schornstein Large holder | SoldNo plan | 690,611 | $1.37 | 946K | 16% | Form 4 |
| Nov 19, 2025 | James P Flynn Director | Bought | 12,100 | $1.88 | 23K | 68% | Form 4 |
| Jul 22, 2025 – Jul 23, 2025 | Nicholas Glover Director | Bought 2 parts | 2,000 | $6.28 average | 13K | New | Form 4 |
- Jun 24James P FlynnDirector · bought 25,000 at $0.8622K25% of stake
- Dec 19, 2025James P FlynnDirector · bought 70,000 at $1.4098K233% of stake
- Dec 18, 2025No planAlexander SchornsteinLarge holder · sold 690,611 at $1.37946K16% of stake
- Nov 19, 2025James P FlynnDirector · bought 12,100 at $1.8823K68% of stake
- Jul 22, 2025 – Jul 23, 2025Nicholas GloverDirector · bought 2,000 at avg $6.2813KNew position
Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.
Peers
Pharmaceutical Preparations · Pick stocks to compare with LITS
Spot a number that looks wrong? Check it in LITS's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing LITS
Create a free account and get 14 days of Premium: every stock and every tool.
- Unlimited stocks
- Stock screener
- Portfolio tracker
- Editable DCF
- Compare side by side
- Unlimited alerts
No card. Moves to Free after, unless you upgrade.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.